Drug intelligence / Profile preview

DA-4001

Development stage: Unknown
Lead developer: Dong-A ST
Modality: Small Molecules
Administration: Topical

Overview

**DA-4001** is a topical scalp formulation of finasteride developed by Dong-A ST for male androgenetic alopecia. Finasteride is a small-molecule 5-alpha-reductase inhibitor that reduces local conversion of testosterone to dihydrotestosterone, an androgen that drives progressive hair-follicle miniaturization in androgenetic alopecia. DA-4001C has been evaluated in clinical studies including a randomized active-controlled Phase 1/2 trial against topical 5% minoxidil and a pharmacokinetic, pharmacodynamic, and safety study in male subjects with androgenetic alopecia.

Targets

SRD5A2 (Steroid 5-alpha-reductase type II)

Beyond the preview

Go deeper on DA-4001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DA-4001.

Explore the full profile